Clinical Trial Update: Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating perioperative mFOLFOX plus pembrolizumab for gastroesophageal junction and stomach adenocarcinoma is currently active/not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Junction Cancer
• Stomach Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• mFOLFOX

Snippet

Sponsor: University of Kansas Medical Center | Conditions: Gastro Esophageal Junction Cancer, Stomach Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING